Novita Pharmaceuticals, Inc. ("Novita"), a privately held, clinical-stage pharmaceutical company dedicated to developing novel cancer drugs through its proprietary fascin inhibitor technology, today ...

Zymeworks Inc. , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, ...

Tempus AI, Inc.'s unique data assets and AI-driven oncology solutions make it a promising buy. Click to read more on why the ...

Roche, hoping to carve out a standard-of-care spot for its PI3K inhibitor Itovebi, now has another leg to stand on with new evidence that shows the drug can extend the lives of certain patients wit | ...

The latest readout from INAVO120 marks the first time a PI3K-inhibiting targeted treatment has shown an overall survival advantage.